Saxenda and the GLP-1 class
Liraglutide was the first daily GLP-1 weight-management drug widely prescribed in the U.S. Although newer drugs have taken market share, liraglutide users developed the same range of injuries: gastroparesis, pancreatitis, gallbladder disease, and ileus.
Qualifying injuries
Documented Saxenda use combined with hospitalization or formal diagnosis of a qualifying injury supports a claim. Earlier prescriptions may face statute-of-limitations issues — do not wait to seek review.